Business Description
Rapport Therapeutics is a Boston-based clinical-stage company working to develop new treatments for disorders of the brain and nervous system. Its lead drug candidate, RAP-219, targets specific receptors in the brain and is being studied as a potential therapy for focal epilepsy, neuropathic pain, and bipolar disorder. The company is also advancing separate research programs aimed at addressing chronic pain, migraines, and hearing and balance disorders.
